China committed to a patent linkage (Hatch-Waxman) regime linking pharmaceutical regulatory approval and patent infringement determinations in the Phase 1 Trade Agreement concluded with the United States in January 2020. The linkage regime is part of a series of pharmaceutical IP related reforms set forth in that Agreement.
With the enactment of China’s revised patent law, as well as the adoption of new rules on patent linkage on July 4, 2021 and a new Judicial Interpretation on July 5, 2021, the basic legislative framework for China’s new patent linkage regime is now in place. But how will these new rules work in practice?
Join us on July 15 – just 10 days after the Judicial Interpretation was promulgated – as we explore the impact of the new patent linkage regime and how it fits into China’s emerging system of administrative and judicial protection of IP.
There is no charge for this event. This is a “rapid response” event, intended to discuss new developments.
Mark Cohen (BCLT), Moderator
John Balzano, Covington
Douglas Clark, Rouse (Hong Kong)
Jill Ge from Allen & Overy, Shanghai
He Jing, Genlaw (Beijing)
Judge Randall R. Rader (ret.)
If you require an accommodation for effective communication (ASL interpreting/CART captioning, alternative media formats, etc.) to fully participate in this event, please contact Nathalie Coletta at firstname.lastname@example.org or 510-643-5518 with as much advance notice as possible and at least 7-10 business days in advance of the event.